Liverpool Lane (@LaneLiverpool) header
Liverpool Lane (@LaneLiverpool) profile picture

Healthcare innovation. For Louisville, the Commonwealth of Kentucky and beyond.

Louisville, KY
Joined April 2023
Photo by Liverpool Lane (@LaneLiverpool)Photo by Liverpool Lane (@LaneLiverpool)Photo by Liverpool Lane (@LaneLiverpool)Photo by Liverpool Lane (@LaneLiverpool)Photo by Liverpool Lane (@LaneLiverpool)Photo by Liverpool Lane (@LaneLiverpool)Photo by Liverpool Lane (@LaneLiverpool)Photo by Liverpool Lane (@LaneLiverpool)Photo by Liverpool Lane (@LaneLiverpool)Photo by Liverpool Lane (@LaneLiverpool)
Liverpool Lane retweeted
Surprise 1: Anthropic acquired a one-person biotech . . . Surprise 2: that person is me Surprise 3: I’m here to tell you all about it Yes, this is what you think it is; after 6 yrs of increasingly loose anonymity: the Professor Oak reveal post …and yes, it has gotten so boring around here that I’m literally doxxing myself to spice up the timeline ------- Ok, allow me to introduce myself. My name is Cody Tranbarger. I mostly tweet, but occasionally find time to dabble in drug dev & starting/building biotechs. My past lives span the VC, crossover, startup continuum; Prof Oak has been my way of keeping a digital foot in those worlds, despite having my physical feet planted elsewhere. The past 18 mo, ‘elsewhere’ was Mithril Medicine, a co. I founded to develop bsAbs for LAMA2-CMD & other ECM-related genetic diseases. Mithril was born out of hands-on building with @MikeNGladstone, @JasonPaulRhodes, @LifeSciVC, & team @atlasventure. Somehow, I made enough half-decent calls along the way (even a broken clock is right twice a day, eh?) to convince them Mithril/I warranted a small seed. While I can hardly rationalize such an outrageously cavalier bet, I’m grateful for it, & I'd partner with Atlas again in a heartbeat. In typical AV fashion, Mithril’s primordial form was virtual, decentralized, & ultra-lean. This stage tends to be short-lived, but for Mithril, it worked surprisingly well, for surprisingly long, thanks in part to the rapid maturation of the AI tools I used liberally. Eventually, Mithril became a bit of an experiment itself - to find the upper bound of how far it could scale as a single operator + a bunch of Claude (+ a stellar bench of part-time consultants). In parallel, I started spending time with @nc_frey, @an1lam, & @CoefficientBio team; and promptly experienced, for the 1st time, AI at the frontier. Soon thereafter, Mithril stopped looking like an experiment, & started looking like a preview of an entirely new operating model. From that spark came “Pipeline-in-a-Person.” The idea immediately resonated when we shared it here back in April; and it was central to the shared vision that led to Anthropic’s acquisition of Mithril, & my joining the team. Why join Anthropic? Three reasons. (1) For Mithril, the programs continue, with more resources & infrastructure behind them, and as much Claude as I can put to work. (2) For me, the chance to start several more programs, & find out how many one person can actually run in parallel - an almost unprecedented luxury for a curious drug hunter. (3) For our mission, a path to institutionalize & scale this new way of working, then put it in the hands of all of biopharma, all over the world - which, candidly, I find the most energizing. Will AI x Bio cure diseases? Unequivocally yes, imo… but not by the route that gets the most airtime. Rather than timeline acceleration & compression, I see orchestration & parallelization as today's low-hanging fruit. Most drug hunters see a handful of go/no-go calls in a career, & spend entirely too much of the rest trading emails (my inbox can attest). Give them the bandwidth to run several programs at once, and the time to focus on scientific judgment, and I’m willing to bet they’ll make better calls. And at scale, better calls translate to more drugs, higher hit rates, broader patient impact, & likely, a disease or 10 or 100 cured. I couldn't be more excited to build toward that future @AnthropicAI. Finally, a heartfelt thank you to BioTwitter/X. The end of anonymity is bittersweet, but if anyone’s earned a proper introduction, you all have. It’s difficult to overstate how much this app has done for me: a decade of education, plenty of friends, many job opportunities, several mentors, a few investors, even a co-founder (fmr). It was the generosity of this community that inspired me to start posting 6 years ago, after just as many years lurking. I hope I’ve been able to pay it forward, in my own small way. But, to be clear, Prof Oak isn’t going anywhere. Same beat, same themes, and now, a front-row seat to drug development at the frontier. Stay tuned for dispatches from the trenches; and remember... Gotta Cure 'Em All
529
1,051
377
14,329
1,717,991
Liverpool Lane retweeted
First part in the series - healthcare companies I think someone should build 1. DME recycling marketplace: A third-party marketplace that re-certifies used durable medical equipment (CPAPs, power wheelchairs, unopened diabetes supplies) so it can be resold legit instead of tossed 2. World's Fair for healthcare: A new World's Fair where people can actually see and touch cutting-edge healthcare tech, like a live Neuralink demo or a Wandercraft exoskeleton. The point is to make people amazed by healthcare again, the way the old fairs did for consumer tech. 3. Instinct for healthcare workers: A personal AI agent built for healthcare employees, with its own login on the org's network, a BAA-covered cloud model, and role-based permissions instead of impersonating you with cached passwords. People are going to use these tools at work no matter what, so someone should build the compliant version.
11
6
1
59
5,218
Liverpool Lane retweeted
Our hackathon focused on improving kicked off with a founder sharing the story of losing his mom in an ER waiting room. We built demos in an hour to fix the ER experience. The participants’ backgrounds are diverse by design with one ER provider per team. The perfect way to kick off our summit. @townhallvntrs @nabla_ai @anomifyinsights @second_op_media & more
2
3
28
3,092
Fiona Marshall (Novartis) on stage at #ARDD2026, Harvard. "Reimagining Drug Discovery Through the Lens of Aging Biology." Day 2 highlights from the world's largest aging research and drug discovery meeting. agingpharma.org/program2026
2
8
22
1,585
Search & Evaluation Strategies for Longevity Therapeutics -- live panel at #ARDD2026. Lilly, GSK, Takeda, Renewal Bio and Nature Biotech on stage together, talking pharma strategy in aging. The pipeline conversation has moved from "if" to "how." agingpharma.org/program2026
3
6
27
2,157
Liverpool Lane retweeted
Huntsville is quickly becoming one of the country’s next biotech hubs, and the momentum is only building as new manufacturing investment and a growing life sciences workforce take root in the Rocket City. 🚀 PhRMA joins @axios today to hear more about how they’re doing it: ow.ly/AcKE50ZY1kE
1
1
1,262
Liverpool Lane retweeted
The National Institute on Aging (NIA) Start-Up Challenge and Accelerator is back for 2027! Are you an early-stage entrepreneur with an idea for technology to advance healthy aging? Submit by Jan 15 to compete for $994,000 in cash prizes, and a slot in the intensive accelerator program: bit.ly/4s1F1yq
11
20
8,203
University of Kentucky researchers at Sanders-Brown are part of a nationwide effort examining how the places people live, work and spend their lives may influence their risk of developing #alzheimers disease and related dementias. @UKYMedicine @UKCPH @ResearchKY medicine.uky.edu/centers/sbc…
2
1
81
Liverpool Lane retweeted
Great night in Lexington at the @AwesomeInc event for the Awesome Fund. Caught up with @SteveHuey and @RenoWeber of @GoodMapsForAll, then heard the Fund 1 update: their first AI company just hit a $250M valuation. That’s a big number for a Kentucky-based fund. They’re raising Fund 2 now. Want in? Talk to @brianraney.
1
5
277
Let's connect.
🤖 Made with AI
1
1
31
"It says here you are not subscribed to our #HealthDistilled newsletter. Explain, please."
1
2
72
Liverpool Lane retweeted
Louisville folks. Sign up. Show up. Register -> evite.me/erY7T7FBGs
1
65
Liverpool Lane retweeted
Norton Leatherman Spine is one of a select group of U.S. sites, and the only site in the region, evaluating an investigational disc cell therapy for lumbar degenerative disc disease. Read more: bit.ly/4xX5jTX
3
3
45
Isn't this what "pac-IQ pac-iq.com/" addresses, @Its_Really_Adam?
Transitions of care are the most frightening aspect of patient care If not done carefully and correctly, pts are harmed. They’re sent out into the healthcare abyss, a complex, fragmented, non-interoperable system.
1
1
94